N/A Completed N=21 Randomized Double-blind Diagnostic

Olopatadine Eye Drops and Allergy Skin Testing

Allergic Rhinitis · allergic conjunctivitis

Source: ClinicalTrials.gov NCT00775658 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Jul 2017

Primary outcomePrimary: The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. — 0.461; 0.464 cm2 — p=0.57

Summary

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

Outcome Measures

Outcome	Result	p-value
PRIMARY The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo.	0.461; 0.464	0.57
PRIMARY The Difference in Area (cm2) of the Flare Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo.	6.95; 8.31	0.09

Eligibility Criteria

Inclusion Criteria

Adults aged 18 to 75 years
Healthy volunteers (no major illnesses or active symptoms)

Exclusion Criteria

Known allergy or hypersensitivity to the drugs or components
Pregnant or nursing women
Women wishing to become pregnant during the study's duration
Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
Dermatographism as evidenced on skin testing on visit 1
Chronic urticaria active within the past 6 months
Severe hypertension
Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
Inability to provide informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00775658). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.